Dabigatran Etexilate Oral Capsule

DRUG3 trials

Sponsors

Herlev and Gentofte Hospital, Vanderbilt University Medical Center

Conditions

Atrial FibrillationAtrial FlutterDeep Vein ThrombosisDevice Related ThrombusLeft Atrial Appendage ThrombosisPulmonary EmbolismWatchman LAA Closure Device

Phase 4

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

Active, not recruitingNCT03129490

Herlev and Gentofte HospitalAtrial Fibrillation, Atrial Flutter

Start: 2023-04-01End: 2027-10-30Target: 11000Updated: 2025-05-18

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

Active, not recruitingNCT03129555

Herlev and Gentofte HospitalDeep Vein Thrombosis, Pulmonary Embolism

Start: 2023-04-01End: 2029-03-31Target: 5000Updated: 2025-05-15

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

CompletedNCT03539055

Vanderbilt University Medical CenterAtrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis +1

Start: 2018-09-01End: 2024-02-29Updated: 2025-06-10

Related Papers

Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial

Journal of Clinical Medicine2021-04-193 citations

Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients

Stroke2018-12-01308 citations